About This Fund
The LSP Dementia Fund is a specialized venture capital fund managed by EQT Life Sciences (formerly Life Sciences Partners, LSP), one of Europe's most experienced healthcare investors with over 30 years of active fund management. Launched in January 2021 and achieving its final close in March 2023 at approximately €260 million — far exceeding its original €100 million target and reaching the fund's hard cap — the LSP Dementia Fund is the world's first dedicated investment vehicle focused exclusively on all stages of dementia drug and medical technology development. It is co-led by Professor Philip Scheltens, MD, PhD, professor emeritus at Amsterdam University Medical Center and one of the world's most recognized authorities in dementia research and clinical neurology.
The LSP Dementia Fund invests across the full development spectrum of dementia therapeutics and medical technology, targeting biotechnology companies and medtech businesses working on disease-modifying therapies, diagnostics, digital health tools, and neuroscience platforms addressing Alzheimer's disease, Lewy body dementia, frontotemporal dementia, and related neurodegenerative conditions. The fund targets a portfolio of 10 to 15 companies and deploys equity capital from early research-stage to late-stage clinical development, bridging the funding gap that has long made dementia one of the most chronically underinvested therapeutic areas relative to its global disease burden. The fund's global mandate allows investment across Europe, North America, and internationally wherever the most promising dementia research is located.
EQT Life Sciences, which integrated LSP in 2022, brings a 30-year track record of European life sciences investing, having raised approximately €3.5 billion across 12 private funds and supported more than 150 healthcare companies. The LSP Dementia Fund attracted a landmark investor base including the Alzheimer's Association, the European Investment Fund, global pharmaceutical companies, and insurance organizations — reflecting both commercial and mission-driven conviction in the fund's thesis. The fund's oversubscription and above-target close validate the thesis that dedicated, expert-led capital allocation to neurodegeneration addresses a critical gap in the global healthcare investment landscape.